Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H0W9

UPID:
CK054_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H0W9; A8K850; Q6FI88; Q6XYB0; Q96EI3; Q96IX1; Q9Y6B4

BACKGROUND:
The protein Ester hydrolase C11orf54 exhibits specific ester hydrolase activity, targeting p-nitrophenyl acetate. This activity underlines its importance in biochemical processes, particularly in the breakdown and synthesis of ester compounds.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions and mechanisms of Ester hydrolase C11orf54 holds promise for the development of new therapeutic methods. The enzyme's role in essential biochemical pathways presents an opportunity for targeted drug discovery and intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.